Cancers, Vol. 16, Pages 1066: Transcriptomic, Proteomic, and Genomic Mutational Fraction Differences Based on HPV Status Observed in Patient-Derived Xenograft Models of Penile Squamous Cell Carcinoma

Cancers, Vol. 16, Pages 1066: Transcriptomic, Proteomic, and Genomic Mutational Fraction Differences Based on HPV Status Observed in Patient-Derived Xenograft Models of Penile Squamous Cell Carcinoma Cancers doi: 10.3390/cancers16051066 Authors: Niki M. Zacharias Luis Segarra Keiko Akagi Natalie Wall Fowlkes Huiqin Chen Angelita Alaniz Carolyn de la Cerda Pedro Pesquera Yuanxin Xi Jing Wang Jad Chahoud Xin Lu Priya Rao Magaly Martinez-Ferrer Curtis A. Pettaway Metastatic penile squamous cell carcinoma (PSCC) has only a 50% response rate to first-line combination chemotherapies and there are currently no targeted-therapy approaches. Therefore, we have an urgent need in advanced-PSCC treatment to find novel therapies. Approximately half of all PSCC cases are positive for high-risk human papillomavirus (HR-HPV). Our objective was to generate HPV-positive (HPV+) and HPV-negative (HPV−) patient-derived xenograft (PDX) models and to determine the biological differences between HPV+ and HPV− disease. We generated four HPV+ and three HPV− PSCC PDX animal models by directly implanting resected patient tumor tissue into immunocompromised mice. PDX tumor tissue was found to be similar to patient tumor tissue (donor tissue) by histology and short tandem repeat fingerprinting. DNA mutations were mostly preserved in PDX tissues and similar APOBEC (apolipoprotein B mRNA editing catalytic polypeptide) mutational fr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research